Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
Background There is great interest in finding ways to identify patients who will develop toxicity to cancer therapies. This has become especially pressing in the era of immune therapy, where toxicity can be long-lasting and life-altering, and primarily comes in the form of immune-related adverse eff...
Saved in:
| Main Authors: | Santosh Kesari, Jose Carrillo, Alexandra Drakaki, Joanne Weidhaas, Mark Scholz, Nicholas Marco, Aaron W Scheffler, Anusha Kalbasi, Kirk Wilenius, Emily Rietdorf, Jaya Gill, Mara Heilig, Caroline Desler, Robert K Chin, Tania Kaprealian, Susan McCloskey, Ann Raldow, Naga P Raja, Donatello Telesca |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-02-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/10/2/e003625.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Germline microRNA-based signatures predict toxicity and response to anti-CTLA-4 therapy
by: Joanne B. Weidhaas, et al.
Published: (2025-07-01) -
Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
by: Patricia Martin‐Romano, et al.
Published: (2020-04-01) -
Pdl1 is a putative lipase that enhances Photorhabdus toxin complex secretion.
by: Guowei Yang, et al.
Published: (2012-01-01) -
Investigation the role of SIRT3, SIRT7, NFATC1, and PDL-1 genes in androgenetic alopecia
by: Hadis Abbasian, et al.
Published: (2024-11-01) -
Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells
by: Abrar Samiea, et al.
Published: (2020-01-01)